Synergistic formulation for relieving gout symptoms

Abstract

We provide a formulation for relieving gout symptoms comprising a synergistic combination of: a. 25 to 200 mg celery seed extract; b. 100 to 1500 mg cherry (genus Prunus ) fruit extract; and c. 1.5 to 10 mg elemental lithium in a lithium salt. We also provide a process to make the formulation, comprising: a. mixing together a synergistic combination of: i. 25 to 200 mg celery seed extract; ii. 100 to 1500 mg cherry (genus Prunus ) fruit extract; iii. 1.5 to 10 mg elemental lithium in a lithium salt; and b. forming the synergistic combination of step (a) into a medicament that when orally administered in an effective amount relieves gout symptoms. 15

It is claimed: 
     
         1 . A process to make a formulation for relieving gout symptoms in a subject in need thereof, comprising:
 a. mixing together a synergistic combination of:
 i. 25 to 200 mg celery seed extract; 
 ii. 100 to 1500 mg cherry (genus  Prunus ) fruit extract; 
 iii. 1.5 to 10 mg elemental lithium in a lithium salt; and 
   b. forming the synergistic combination of step (a) into a medicament that when orally administered to the subject in an effective amount relieves gout symptoms.   
     
     
         2 . The process of  claim 1 , wherein
 a. the celery seed extract is a first material that when administered to the subject inhibits formation of a uric acid in the subject;   b. the cherry (genus  Prunus ) fruit extract is a second material that when orally administered to the subject increases an elimination of the uric acid in the subject; and   c. the elemental lithium in the lithium salt is a third material that when orally administered to the subject interferes with formation of uric acid crystals in the subject.   
     
     
         3 . The process of  claim 1 , wherein the lithium salt is selected from the group consisting of lithium orotate, lithium aspartate, lithium proteinate, lithium carbonate, and mixtures thereof. 
     
     
         4 . The process of  claim 1 , wherein the lithium salt is lithium orotate, lithium aspartate, or a mixture thereof. 
     
     
         5 . The process of  claim 1 , wherein the celery seed extract is standardized to contain at least 50% 3-n-butylphthalide calculated as total phthalides. 
     
     
         6 . The process of  claim 1 , wherein the cherry (genus  Prunus ) fruit extract is sweet cherry ( Prunus avium ), tart cherry ( Prunus cerasus ), Amur choke cherry ( Prunus maackii ), wild black cherry ( Prunus serotina ), or mixtures thereof. 
     
     
         7 . The process of  claim 1 , wherein the cherry (genus Prunus) fruit extract is at least a 5:1 concentrate by weight. 
     
     
         8 . The process of  claim 1 , wherein the medicament is a tablet, a capsule, a pill, a softgel, a suspension, a chewable, a lozenge, or a powder. 
     
     
         59 . The process of  claim 1 , wherein the medicament comprises less than 10 wt % inert filler. 
     
     
         10 . A formulation comprising a synergistic combination of:
 a. 25 to 200 mg celery seed extract;   b. 100 to 1500 mg cherry (genus  Prunus ) fruit extract; and   c. 1.5 to 10 mg elemental lithium in a lithium salt; wherein the formulation is effective for relieving gout symptoms in a subject in need thereof when an effective amount of the formulation is orally administered to the subject.   
     
     
         11 . The formulation of  claim 10 , wherein
 a. the celery seed extract is a first material that when administered to the subject inhibits formation of a uric acid in the subject;   b. the cherry (genus  Prunus ) fruit extract is a second material that when orally administered to the subject increases an elimination of the uric acid in the subject; and   c. the elemental lithium in the lithium salt is a third material that when orally administered to the subject interferes with formation of uric acid crystals in the subject.   
     
     
         12 . The formulation of  claim 10 , wherein the synergistic combination is formed into a medicament. 
     
     
         13 . The formulation of  claim 12 , wherein the medicament is a tablet, a capsule, a pill, a softgel, a suspension, a chewable, a lozenge, or a powder. 
     
     
         14 . The formulation of  claim 10 , additionally comprising less than 10 wt % inert filler. 
     
     
         15 . The formulation of  claim 10 , wherein the lithium salt is lithium orotate, lithium aspartate, lithium proteinate, lithium carbonate, or mixtures thereof. 
     
     
         16 . The formulation of  claim 10 , wherein the lithium salt is lithium orotate, lithium aspartate, or a mixture thereof. 
     
     
         17 . The formulation of  claim 10 , wherein the celery seed extract is standardized to contain at least 50% 3-n-butylphthalide calculated as total phthalides. 
     
     
         18 . The formulation of  claim 10 , wherein the cherry (genus  Prunus ) fruit extract is sweet cherry ( Prunus avium ), tart cherry ( Prunus cerasus ), Amur choke cherry ( Prunus maackii ), wild black cherry ( Prunus serotina ), or mixtures thereof. 
     
     
         19 . The formulation of  claim 10 , wherein the cherry (genus  Prunus ) fruit extract is at least a 5:1 concentrate by weight. 
     
     
         20 . The formulation of  claim 10 , wherein the formulation can be administered in separate medicaments.